Cord Blood News Volume 5.45 | Nov 14 2013

MSCs vs. MSCs Combined with CB for Engraftment Failure Following Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Labeled, Randomized Trial
Researchers prospectively evaluated the effects and safeties of mesenchymal stem cells (MSCs) alone and combined with cord blood (CB) for engraftment failure. Twenty two patients were randomized to receive MSCs or MSCs plus CB. [Biol Blood Marrow Transplant] Abstract

Treatment with Placenta-Derived Mesenchymal Stem Cells Mitigates Development of Bronchiolitis Obliterans in a Murine Model
Researchers investigated the hypothesis that treatment with placenta-derived human mesenchymal stem cells reduces the development of bronchiolitis obliterans in a murine heterotopic tracheal transplant model. [J Thorac Cardiovasc Surg] Abstract

Inhibition of Non-Muscle Myosin II Leads to G₀/G₁ Arrest of Wharton’s Jelly-Derived Mesenchymal Stromal Cells
When cultured in the presence of blebbistatin, an inhibitor of non-muscle myosin II adenosine triphosphatase activity, Wharton’s jelly-derived mesenchymal stromal cells exhibited dose-dependent reduction in proliferative potential along with increase in cell size and induction of early senescence. [Cytotherapy] Abstract

Amniotic Fluid Stem Cells Prevent β-Cell Injury
Investigators used a chemically induced mouse model of type 1 diabetes to determine whether amniotic fluid stem cells could play a role in modulating β-cell injury and restoring β-cell function. [Cytotherapy] Abstract

Sunitinib Effects on the Radiation Response of Endothelial and Breast Tumor Cells
Investigators conducted experiments in vitro to discern the effects of radiation combined with the anti-angiogenic Sunitinib on endothelial (HUVEC) and tumor (MDA-MB-231) cells, and further compared findings to results obtained in vivo. [Microvasc Res] Abstract

Stem Cell Recruitment Factors Secreted from Cord Blood-Derived Stem Cells that Are Not Secreted from Mature Endothelial Cells Enhance Wound Healing
Researchers examined the wound healing effect of secretory factors released from human cord blood-derived stem cells and human umbilical vascular endothelial cells on cutaneous excisional wound models. [In Vitro Cell Dev Biol Anim] Abstract

Brain-Derived Neurotrophic Factor-Modified Umbilical Cord Mesenchymal Stem Cell Transplantation Improves Neurological Deficits in Rats with Traumatic Brain Injury
This study explored the effect of brain-derived neurotrophic factor gene-modified umbilical cord mesenchymal stem cell transplantation on neurological functional improvement in rats after brain trauma. [Int J Neurosci] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

$100 Million Gift Launches Sanford Stem Cell Clinical Center
In a bold and singular step toward delivering the therapeutic promise of human stem cells, businessman and philanthropist T. Denny Sanford has committed $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego. The Sanford Center will accelerate development of drugs and cell therapies inspired by and derived from current human stem cell research; establishing, promoting and disseminating clinical trials and patient therapies that will help more quickly transform promise into reality. [University of California, San Diego] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Clinical Researcher – Hematopoietic Stem Cell Transplant Program (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Fellows – Isolation of Stem Cells from Placenta and Amniotic Fluid (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

PhD Studentship – Identifying Drugs to Improve the Utility of Bone Marrow and Cord Blood Transplantation (Cardiff University)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Postdoctoral Position – Patient-Specific Stem Cell Lines: Disease Modeling, Repair and Transplantation (Columbia University)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.